# Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma

> **NCT03982680** · PHASE2 · UNKNOWN · sponsor: **Jiangmen Central Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Cholangiocarcinoma

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Gemcitabine
- **DRUG:** 5- fluorine pyrimidine

## Key facts

- **NCT ID:** NCT03982680
- **Lead sponsor:** Jiangmen Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-13
- **Primary completion:** 2021-05-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03982680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03982680, "Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03982680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*